Compare NOAH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | ALT |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.4M | 573.8M |
| IPO Year | 2010 | 2005 |
| Metric | NOAH | ALT |
|---|---|---|
| Price | $7.58 | $2.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $10.62 | ★ $17.11 |
| AVG Volume (30 Days) | 90.5K | ★ 3.1M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.11% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $7.60 | $2.55 |
| 52 Week High | $12.45 | $6.44 |
| Indicator | NOAH | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 29.08 | 27.07 |
| Support Level | N/A | $2.57 |
| Resistance Level | $8.17 | $3.35 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 3.65 | 6.29 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.